Should Testosterone Be Removed From The Controlled Drug List?

Viewing This Video Is A Member Exclusive Feature

But you don’t need membership to get Dr. O’Connor’s insight on this topic, it’s in the summary, key takeaways, and related drugs and conditions below.

Want to watch the full video? Join the Health Portal Today.

Join Now

Already a member? Sign In

Timeline

00:00

Dr. O’Connor supports regulated access and proposes removing testosterone from the controlled drug list. He connects his argument with the history of steroid use in competitive sports.

02:20

The discussion shifts to his society’s response to an FDA request for comments. Dr. O’Connor emphasizes access for adults who need testosterone, appropriate assessment, and harm reduction through ongoing care.

04:10

Dr. O’Connor addresses prostate cancer, the saturation model, and controversy about treating men with existing cancer. He closes by distinguishing improved medical access from unrestricted over-the-counter availability.

Video Summary

Thomas O'Connor advocates easier access to testosterone while preserving medical regulation and ongoing monitoring. Responding to a viewer’s argument that legalization could encourage research and innovation, he supports reform while distinguishing supervised treatment from unrestricted availability.

He proposes removing testosterone from the controlled drug list and connects its scheduling history with concerns about performance-enhancing drugs in competitive sports. He discusses Ben Johnson’s steroid use as an example of how athletic controversies shaped attitudes toward testosterone and anabolic steroids.

Dr. O’Connor also describes his society’s response to an FDA request for comments. He emphasizes access for adults who need testosterone, appropriate evaluation, and continued management of treatment effects. Removing controlled status is his proposed policy change rather than a description of current law.

The discussion then turns to prostate cancer and the testosterone saturation model. Dr. O’Connor challenges the claim that testosterone necessarily causes prostate cancer while stressing that prostate assessment remains important. He acknowledges controversy surrounding testosterone treatment in men with existing prostate cancer and cautions against prescribing without considering the diagnosis.

He closes by rejecting unrestricted over-the-counter access. His position combines improved accessibility with regulated treatment, an understanding of potential side effects, and ongoing medical supervision.

Drug Callouts

Testosterone

Testosterone is an androgen hormone used medically to replace deficient testosterone in men with certain forms of hypogonadism. Dr. O’Connor advocates changing its controlled status while preserving patient assessment, regulated prescribing, side-effect counseling, and ongoing monitoring.

Estrogen

Estrogens are hormones involved in reproductive function and other body processes that are also used as medications for several medical conditions. Dr. O’Connor uses estrogen-associated blood clot risk as a comparison when questioning why testosterone is a controlled substance, rather than recommending estrogen treatment.

Condition Callouts

Prostate Cancer

Prostate cancer is a disease in which abnormal cells grow uncontrollably in the prostate gland. For men considering or using testosterone, Dr. O’Connor emphasizes prostate evaluation and acknowledges that treatment in men with existing cancer requires particular caution and remains controversial.

Blood Clots

Blood clots are masses formed from blood components that can obstruct circulation when they develop inside blood vessels. In this discussion about testosterone access, Dr. O’Connor raises estrogen-related clot risk to illustrate that a medication’s health risks and its controlled-substance classification are separate considerations.

Key Takeaways

Testosterone is currently a Schedule III controlled substance under U.S. federal law; removing that classification is a proposed policy change, not the current legal position.
A controlled-substance designation does not mean a medication has no legitimate medical use, and testosterone can be prescribed for appropriate medical indications.
Improving access to testosterone does not require abandoning regulation, patient assessment, or ongoing monitoring.
The absence of evidence that TRT causes prostate cancer does not establish that testosterone prevents cancer or is appropriate for every man with an existing diagnosis.
Prostate health remains part of testosterone treatment assessment even when a clinician challenges the claim that testosterone causes prostate cancer.
Dr. O’Connor’s proposed approach combines adult access with informed understanding of side effects and continued medical supervision, rather than unrestricted over-the-counter use.